Eliaz Therapeutics has started a Regulation Crowdfunding round to fund GLP safety studies and first-in-human trials of XGal-3, an apheresis device targeting Galectin-3 to treat sepsis. The device has FDA Breakthrough Device Designation and aims to address sepsis by removing a key inflammatory protein, potentially improving survival. With $8M raised and strong preclinical data, the company plans to expand clinical development and explore broader applications for Galectin-3-related diseases.
The General Counsel of Figma has sold 211,599 shares, generating $6.3 million in proceeds. This significant insider sale could indicate personal financial planning or a shift in confidence, which investors might watch closely. The impact on Figma's s...
PancakeSwap has introduced $SHEINx, a synthetic token that tracks the price of SHEIN’s stock listed on the Hong Kong Stock Exchange, allowing DeFi users to gain exposure to SHEIN’s equity without using traditional brokerage accounts. SHEIN recently w...
Rosen Law Firm has announced an investigation into Build-A-Bear Workshop, Inc. (BBW) regarding potential securities claims. The firm alleges that Build-A-Bear may have provided materially misleading business information to the investing public. This ...
Cash Cat (CASHCAT) memecoin surged over 29% in 24 hours, reaching a new peak of $0.30 driven by a trading boom on the Robinhood Chain. It is now the second largest memecoin by market cap on the chain, benefiting from a gold rush in memecoin activity ...
FuelCell Energy reported disappointing third-quarter results with sales and earnings per share falling short of expectations, partly due to selling a 30 MW tranche below cost. The company raised nearly $300 million through a public offering and marke...
